CA2362527A1 - A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer - Google Patents

A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer Download PDF

Info

Publication number
CA2362527A1
CA2362527A1 CA002362527A CA2362527A CA2362527A1 CA 2362527 A1 CA2362527 A1 CA 2362527A1 CA 002362527 A CA002362527 A CA 002362527A CA 2362527 A CA2362527 A CA 2362527A CA 2362527 A1 CA2362527 A1 CA 2362527A1
Authority
CA
Canada
Prior art keywords
seq
nucleic acid
prostate cancer
antibody
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002362527A
Other languages
French (fr)
Other versions
CA2362527C (en
Inventor
Gang An
Robert Veltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratory Corp of America Holdings
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362527A1 publication Critical patent/CA2362527A1/en
Application granted granted Critical
Publication of CA2362527C publication Critical patent/CA2362527C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/85Reproductive organs or embryos
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Abstract

Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences.
Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.

Claims (35)

1. An isolated nucleic acid segment comprising a full length sequence or the full length complement of a sequence selected from the group consisting of SEQ ID
NO:1, SEQ ID NO:3 and SEQ ID NO:4.
2. An isolated nucleic acid molecule of a size between about 14 and 100 bases in length, identical in sequence to a contiguous portion of at least 14 bases of a nucleic acid or its complement selected from the group consisting of SEQ ID NO:3 and SEQ
ID NO:4.
3. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
4. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
5. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
6. The isolated nucleic acid molecule of claim 2, of a size of between about and 100 bases in length.
7. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:1.
8. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:3.
9. The isolated nucleic acid according to claim 1, wherein the sequence is SEQ
ID NO:4.
10. An isolated nucleic acid encoding a full length amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5.
11. An isolated polypeptide comprising a full length amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:5.
12. An isolated peptide of a size between 10 and 25 amino acids in length, identical in sequence to a contiguous portion of at least 10 amino acid residues of SEQ ID NO:4.
13. An isolated peptide of a size between 10 and 65 amino acids in length, identical in sequence to a contiguous portion of at least 10 amino acid residues of SEQ ID NO:5.
14. A method for detecting prostate cancer cells in a biological sample comprising the step of detecting a prostate cancer marker in said sample, wherein said prostate cancer marker is a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
15. The method of claim 14, further comprising the steps of a) amplifying nucleic acids from said sample to form nucleic acid amplification products;
b) contacting said nucleic acid amplification products with an oligonucleotide probe that will hybridize under stringent conditions with said prostate cancer marker;
c) detecting the nucleic acid amplification products which hybridize with said probe; and d) measuring the amount of said nucleic acid amplification products that hybridize with said probe, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
16. The method of claim 15, in which said oligonucleotide probe is selected to bind specifically to an isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
17. The method of claim 14, further comprising the steps of a) providing primers that will selectively amplify said prostate cancer marker;
b) amplifying said nucleic acids with said primers to form nucleic acid amplification products;
c) detecting said nucleic acid amplification products; and d) quantifying said nucleic acid amplification products, wherein an increased amount of said prostate cancer marker in said sample, relative to the amount of said marker in normal tissue samples, is indicative of the prostate cancer cells.
18. The method of claim 17, wherein said primers are selected to amplify a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.
19. The method of claim 16, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
20. The method of claim 16, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product binding to a probe specific for said prostate cancer marker.
21. The method of claim 18, further comprising determining the prognosis of prostate cancer patients by quantifying the nucleic acid amplification product.
22. The method of claim 18, further comprising determining the diagnosis of human prostate cancer by quantifying the nucleic acid amplification product.
23. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polypeptide comprising SEQ ID NO:2;
c) providing an antibody that reacts immunologically against said polypeptide; and d) administering an effective amount of said antibody to an individual with prostate cancer.
24. A method of treating individuals with prostate cancer, comprising the steps of:
a) obtaining a sample of tissue from an individual with prostate cancer;
b) screening said sample for the expression of a polynucleotide comprising SEQ ID NO:1;

c) providing an antisense DNA molecule that encodes an RNA molecule that binds to said polynucleotide;
d) providing said antisense DNA molecule in the form of a human vector containing appropriate regulatory elements for the production of said RNA molecule; and e) administering an effective amount of said vector to an individual with prostate cancer.
25. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) a primer pair for amplifying a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID
NO:4; and (b) containers for each of said primers.
26. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an oligonucleotide probe which binds under high stringency conditions to an isolated nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4; and (b) a container for said probe.
27. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a polypeptide comprising SEQ ID NO:5; and (b) a container for said antibody.
28. A method for detecting prostate cancer cells in biological samples, comprising the following steps:
(a) providing an antibody that binds immunologically to a peptide comprising SEQ ID NO:5;
(b) contacting a human tissue sample with said antibody;
(c) separating antibody bound to said tissue sample from unbound antibody; and (d) detecting the bound antibody.
29. A kit for use in detecting prostate cancer cells in a biological sample, comprising:
(a) an antibody which binds immunologically to a polypeptide comprising an amino acid sequence selected from SEQ ID NO:5; and (b) a container for said antibody.
30. A method for treating individuals with prostate cancer, comprising the following steps:
(a) selecting a polypeptide comprising a sequence selected from SEQ ID
NO:5;
(b) providing an inhibitor designed to bind specifically to said polypeptide;
and (c) administering an effective dosage of said inhibitor to a prostate cancer patient.
31. The isolated nucleic acid according to claim 1, wherein said nucleic acid is incorporated into a human expression vector.
32. The isolated nucleic acid according to claim 10, wherein said nucleic acid is incorporated into a human expression vector.
33. The method of claim 24, wherein said antisense DNA molecule encodes a full length complementary sequence to SEQ ID NO:1.
34. The method of claim 23, wherein said antibody is in the form of a single-chain antibody.
35. The method of claim 34, wherein said administering step comprises providing an expression vector that encodes said single-chain antibody.
CA2362527A 1999-02-09 2000-01-24 A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer Expired - Fee Related CA2362527C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/247,188 1999-02-09
US09/247,188 US6156515A (en) 1999-02-09 1999-02-09 Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
PCT/US2000/002052 WO2000047773A1 (en) 1999-02-09 2000-01-24 A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer

Publications (2)

Publication Number Publication Date
CA2362527A1 true CA2362527A1 (en) 2000-08-17
CA2362527C CA2362527C (en) 2011-07-12

Family

ID=22933947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2362527A Expired - Fee Related CA2362527C (en) 1999-02-09 2000-01-24 A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer

Country Status (8)

Country Link
US (6) US6156515A (en)
EP (2) EP1734134B1 (en)
AT (1) ATE329057T1 (en)
AU (1) AU2740100A (en)
CA (1) CA2362527C (en)
DE (1) DE60028544T2 (en)
ES (1) ES2394093T3 (en)
WO (1) WO2000047773A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110006A1 (en) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarkers of prostate cancer and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
EP1344064A2 (en) * 2000-11-01 2003-09-17 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
AU2002236579A1 (en) * 2000-11-06 2002-05-21 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
WO2002038810A2 (en) * 2000-11-06 2002-05-16 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
AU2002217991A1 (en) * 2000-11-21 2002-06-03 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
GB0119852D0 (en) * 2001-08-15 2001-10-10 Univ York Baculovirus
AU2002324902A1 (en) * 2001-09-06 2003-03-24 The Burnham Institute Serine/threonine hydrolase proteins and screening assays
AU2002360305A1 (en) * 2001-10-26 2003-05-06 Immunivest Corporation Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample
US20050069889A1 (en) * 2001-12-21 2005-03-31 Naoki Nihei Novel metastasis suppressor gene on human chromosome 8
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
US7713693B1 (en) 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20070029205A1 (en) * 2005-08-08 2007-02-08 Shoou-Aaey Chen Method of surface treatment for metal and nonmetal surfaces
US20100294681A1 (en) * 2007-06-05 2010-11-25 Dylina Tim J Golf bag
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US20130190321A1 (en) * 2012-01-23 2013-07-25 West Chester University Of Pennsylvania Methods and compositions relating to proliferative disorders of the prostate
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4883750A (en) * 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1987000880A1 (en) * 1985-08-09 1987-02-12 Soederstroem Gert Safety device
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU622104B2 (en) * 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) * 1987-06-19 1995-01-24 Siska Diagnostics Inc Method and kits for the amplification and detection of nucleic acid sequences
WO1989001025A2 (en) * 1987-07-24 1989-02-09 Allrutan Bio-Produkte Gmbh Foodstuffs, dietetic foodstuffs, foodstuff additives, cosmetics and drugs based on yeast
CA1323293C (en) * 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
WO1989006700A1 (en) * 1988-01-21 1989-07-27 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) * 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
DK0517895T3 (en) * 1990-12-14 1997-04-07 Univ California Chimeric chains for receptor-linked signal transduction pathways
US5262311A (en) * 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
ATE231920T1 (en) * 1992-03-11 2003-02-15 Dana Farber Cancer Inst Inc METHOD TO CLONE MRNA
DE69332642T2 (en) * 1992-10-29 2003-10-02 Thomas Jefferson University Ph METHODS FOR DETECTING MICROMETASAS IN PROSTATE CANCER
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
US5639656A (en) * 1994-03-31 1997-06-17 Medical College Of Hampton Road Antibodies reactive with biological markers of benign prostate hyperplasia
US5658730A (en) * 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
JPH10513044A (en) * 1995-01-20 1998-12-15 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Human prostate specific reductase
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) * 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
US6156515A (en) 1999-02-09 2000-12-05 Urocor, Inc. Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (en) 2010-03-24 2014-08-29 Inst Francais Du Petrole NEW AREA OF CATALYST REGENERATION DIVIDED IN SECTORS FOR REGENERATIVE CATALYTIC UNITS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110006A1 (en) * 2007-03-12 2008-09-18 Miraculins Inc. Biomarkers of prostate cancer and uses thereof

Also Published As

Publication number Publication date
EP1734134B1 (en) 2012-08-29
US6369195B1 (en) 2002-04-09
EP1151140B9 (en) 2007-01-10
EP1734134A2 (en) 2006-12-20
US20080044416A1 (en) 2008-02-21
EP1151140A1 (en) 2001-11-07
DE60028544D1 (en) 2006-07-20
DE60028544T2 (en) 2007-06-06
US20110286917A1 (en) 2011-11-24
US7993830B2 (en) 2011-08-09
WO2000047773A1 (en) 2000-08-17
ES2394093T3 (en) 2013-01-17
US20020068281A1 (en) 2002-06-06
AU2740100A (en) 2000-08-29
US20030017472A1 (en) 2003-01-23
US6156515A (en) 2000-12-05
EP1151140B1 (en) 2006-06-07
ATE329057T1 (en) 2006-06-15
CA2362527C (en) 2011-07-12
EP1151140A4 (en) 2002-12-18
EP1734134A3 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
CA2362527A1 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
CA2262403A1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
KR101446626B1 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
RU2721916C2 (en) Methods for prostate cancer prediction
CA2269634A1 (en) Reagents and methods useful for detecting diseases of the breast
CA2318354A1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2488404A1 (en) Genes and polypeptides relating to human colon cancers
JP2004528810A5 (en)
CA2380550A1 (en) C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
AU2014373927B2 (en) Prostate cancer gene profiles and methods of using the same
JP2010508855A5 (en)
JP2003508022A5 (en)
CA2418422A1 (en) Novel kallikrein gene
KR20180028028A (en) Composition and method for improving sensitivity and specificity on detection of nucleic acids with using dCas9 protein and gRNA for binding to target nucleic acid sequence
CA2263895A1 (en) Therapeutic and diagnostic applications of perlecan domain i splice variants
JP2009523004A5 (en)
KR20020007362A (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
CA2287571A1 (en) Reagents and methods useful for detecting diseases of the prostate
CA2232237A1 (en) Reagents and methods useful for detecting diseases of the breast
JPH08500731A (en) Diagnostic method
JP2000500650A (en) Detection of breast cancer virus-like sequences in human breast cancer
JP4344165B2 (en) Keloid diagnosis method
US6379951B1 (en) Compounds for immunotherapy of breast cancer and methods for their use
JP2005052061A (en) Method for detecting target nucleic acid using zinc finger protein
KR101683961B1 (en) Recurrence Marker for Diagnosis of Bladder Cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160125